- Email: [email protected]
456. Precise Manipulation of a Herpesvirus for Gene Therapy
" " ?. !" 2 - 2/ - ' / -C(/ ( 1 1
$ C ' C . " 1
$ 2 C%D '
"
3
$" 8&= C 3 C 8&= 1 C(."8
" C C
C 8&= $C)"A8 3 C ' C C(. ' A)("
3 C)"A8 -3 ,9H
/ C 8&= " #)" '"$
( C "
C(."8 C)"A
2% ' *
C)"A8 3 C)" ';6& 3 ' ?
C( 2 C "$ ' C
$ C 3 $%C
" C(."8
2
C 8&= 1 C ( " ' 2 "
>3
454. An Easy Method T o Produce High Amount To Apathogenic HSV -1 Amplicon V ectors HSV-1 Vectors Cécile C. Zaupa,1 Alberto L. L. Epstein.1 1 Centre de Génétique Moléculaire et Cellulaire, CNRS-UMR 5534. Université Claude Bernard Lyon 1, Villeurbanne, France. C "
C(."8
$*' 1 - 899 / 3
"3!
3
-C(."8DD/ 3 - >"@>=9/
2
-D > ,998 C 8,78B8"8B;/C C(."8DD
"
E
C(."8 DD
C(."8DDΔ< C(."8DD 3
>= !6 3 =6&)@?! )@?) C(."8DDΔ< !6 3
2CA",8 )@? >= C#.
2CA"*'B % ,
C(."8DDΔ<
C(."8DD 99& C(."8 DDΔ<
C(."8DD
S148
"
C(."8DDΔ<
" 3 !6 - >"@>" @*'/ ! ;H
3
0
455. Multiple Administration of NV1020, an Oncolytic HSV -1, Results in Increased Anti-T umor Efficacy in HSV-1, Anti-Tumor Rodents with Colorectal Metastases to Liver Brian C. Horsburgh,1 Yuman Fong,2 Sandeep Malhotra,2 Keith Delman,2 Tina Rogers,3 Joanna J. Peterkin,1 Frank Tufaro.1 1 MediGene Inc, San Diego, CA, United States; 2MSKCC, New York, NY, United States; 3SRI, Birmingham, AL, United States. *.89,9 "
C(. '
"
' 1
*.89,9 E
-/ -/ -/ " 3 *.89,9 " ,B%2% # % ,B #
E C(."] C(." 2%
C(." " ;,
*.89,9 !2(
#
7 8 B 8 ; 8 : ?
"
] *.89,9
"
% -!O99&/ 2
-!O9998/ C " 3 C(." 8 B 8 ;
3 -8/ " 3 *.89,9
-,/
1
" ] -= & / -=/ "
*.89,9 >
#
) #
456. Precise Manipulation of a Herpesvirus for Gene Therapy Rob E. White,1 Adrian Whitehouse.1 1 Molecualar Medicine Unit, St James′s University Hospital, Leeds, United Kingdom.
> "2 ->2./
"8 - // ′ ", - I C.(/ 3 -
1 / C.( C.(
$*' 8&9 889 ′ 1 ′
86 1 ;&
3
C.( -2'/ 2' 3 Molecular Therapy Vol. 5, No. 5, May 2002, Part 2 of 2 Parts Copyright © The American Society of Gene Therapy
" !"! ## @
- / 1 -)/
)@? 8&
2'
3 &9
,9 0 C.("2'
C.(
C.("2' 3
C.( 0
C.( 2' 4 @ '"
3 @
?! #. 3 '
0
1
3 1 -)/
3 G
3 ,9 " 3
457. Improved Efficacy of Replication Competent Oncolytic HSV -1 V ector G47 Δ in Brain T umors HSV-1 Vector G47Δ Tumors Yasushi Ino,1 Robert L. Martuza,1 Samuel D. Rabkin,1 Tomoki Todo.1 1 Molecular Neurosurgery Laboratory, Massachusetts General Hospital, Boston, MA, United States. @ 3 8 -C(."8/
,9; " C(."8 7 γ7 5 !B ,9;
@
,9;
!
3
C C(."8
#C
γ7" C(."8 ,9;
6;Δ
α&;
B'' ,9; 2
α &;
- '!/ #C " "
" 3 B''
γ7" C(."8 6;Δ 3
4:;# 48=:#
6;Δ 89 899 ,9; '
6;Δ 3
6 &
,9; C
3 #C 3 6;Δ"
#C 3 ,9;" "
4:;#
,
6;Δ
6: " ,9"
,9; 6;Δ ,9; 4:;# * , '%< '%<
Molecular Therapy Vol. 5, No. 5, May 2002, Part 2 of 2 Parts Copyright © The American Society of Gene Therapy
* , 6;Δ -,389& /
3
,9;"
$
6;Δ ,9;
C(."8 '%< ,389B 6;Δ
" !"! ## 458. Heparan Sulfate Proteoglycans, and Not CAR or Integrins, Are the Major Receptors for Hepatic Adenoviral T ransduction In V ivo Transduction Vivo Ted A. Smith,1 Neeraja Idamakanti,1 Patrick M. Wright,1 Jennifer Marshall-Neff,1 Michele L. Rollence,1 Glen R. Nemerow,2 Christine Mech,1 Anne Pinkstaff,1 Michele Kaloss,1 Michael Kaleko,1 Susan C. Stevenson.1 1Genetic Therapy, Inc., A Novartis Company, Gaithersburg, MD, United States; 2Department of Immunology, The Scripps Research Institute, La Jolla, CA, United States. ' E "
3 (
7
3 " -'@/ ( 1
'@0
'2 '@
C
* 3
@ $ α
. '2
="
'82 '@ @ -C( / 0
C( -AA A/ D
'82 0
'2
.
'2 %
'&65 '82 .
@ $ C
'&65 ) C( '@ '2
C(
E G
1
"
'@ G C(
S149
$ C ' C . " 1
$ 2 C%D '
"
3
$" 8&= C 3 C 8&= 1 C(."8
" C C
C 8&= $C)"A8 3 C ' C C(. ' A)("
3 C)"A8 -3 ,9H
/ C 8&= " #)" '"$
( C "
C(."8 C)"A
2% ' *
C)"A8 3 C)" ';6& 3 ' ?
C( 2 C "$ ' C
$ C 3 $%C
" C(."8
2
C 8&= 1 C ( " ' 2 "
>3
454. An Easy Method T o Produce High Amount To Apathogenic HSV -1 Amplicon V ectors HSV-1 Vectors Cécile C. Zaupa,1 Alberto L. L. Epstein.1 1 Centre de Génétique Moléculaire et Cellulaire, CNRS-UMR 5534. Université Claude Bernard Lyon 1, Villeurbanne, France. C "
C(."8
$*' 1 - 899 / 3
"3!
3
-C(."8DD/ 3 - >"@>=9/
2
-D > ,998 C 8,78B8"8B;/C C(."8DD
"
E
C(."8 DD
C(."8DDΔ< C(."8DD 3
>= !6 3 =6&)@?! )@?) C(."8DDΔ< !6 3
2CA",8 )@? >= C#.
2CA"*'B % ,
C(."8DDΔ<
C(."8DD 99& C(."8 DDΔ<
C(."8DD
S148
"
C(."8DDΔ<
" 3 !6 - >"@>" @*'/ ! ;H
3
0
455. Multiple Administration of NV1020, an Oncolytic HSV -1, Results in Increased Anti-T umor Efficacy in HSV-1, Anti-Tumor Rodents with Colorectal Metastases to Liver Brian C. Horsburgh,1 Yuman Fong,2 Sandeep Malhotra,2 Keith Delman,2 Tina Rogers,3 Joanna J. Peterkin,1 Frank Tufaro.1 1 MediGene Inc, San Diego, CA, United States; 2MSKCC, New York, NY, United States; 3SRI, Birmingham, AL, United States. *.89,9 "
C(. '
"
' 1
*.89,9 E
-/ -/ -/ " 3 *.89,9 " ,B%2% # % ,B #
E C(."] C(." 2%
C(." " ;,
*.89,9 !2(
#
7 8 B 8 ; 8 : ?
"
] *.89,9
"
% -!O99&/ 2
-!O9998/ C " 3 C(." 8 B 8 ;
3 -8/ " 3 *.89,9
-,/
1
" ] -= & / -=/ "
*.89,9 >
#
) #
456. Precise Manipulation of a Herpesvirus for Gene Therapy Rob E. White,1 Adrian Whitehouse.1 1 Molecualar Medicine Unit, St James′s University Hospital, Leeds, United Kingdom.
> "2 ->2./
"8 - // ′ ", - I C.(/ 3 -
1 / C.( C.(
$*' 8&9 889 ′ 1 ′
86 1 ;&
3
C.( -2'/ 2' 3 Molecular Therapy Vol. 5, No. 5, May 2002, Part 2 of 2 Parts Copyright © The American Society of Gene Therapy
" !"! ## @
- / 1 -)/
)@? 8&
2'
3 &9
,9 0 C.("2'
C.(
C.("2' 3
C.( 0
C.( 2' 4 @ '"
3 @
?! #. 3 '
0
1
3 1 -)/
3 G
3 ,9 " 3
457. Improved Efficacy of Replication Competent Oncolytic HSV -1 V ector G47 Δ in Brain T umors HSV-1 Vector G47Δ Tumors Yasushi Ino,1 Robert L. Martuza,1 Samuel D. Rabkin,1 Tomoki Todo.1 1 Molecular Neurosurgery Laboratory, Massachusetts General Hospital, Boston, MA, United States. @ 3 8 -C(."8/
,9; " C(."8 7 γ7 5 !B ,9;
@
,9;
!
3
C C(."8
#C
γ7" C(."8 ,9;
6;Δ
α&;
B'' ,9; 2
α &;
- '!/ #C " "
" 3 B''
γ7" C(."8 6;Δ 3
4:;# 48=:#
6;Δ 89 899 ,9; '
6;Δ 3
6 &
,9; C
3 #C 3 6;Δ"
#C 3 ,9;" "
4:;#
,
6;Δ
6: " ,9"
,9; 6;Δ ,9; 4:;# * , '%< '%<
Molecular Therapy Vol. 5, No. 5, May 2002, Part 2 of 2 Parts Copyright © The American Society of Gene Therapy
* , 6;Δ -,389& /
3
,9;"
$
6;Δ ,9;
C(."8 '%< ,389B 6;Δ
" !"! ## 458. Heparan Sulfate Proteoglycans, and Not CAR or Integrins, Are the Major Receptors for Hepatic Adenoviral T ransduction In V ivo Transduction Vivo Ted A. Smith,1 Neeraja Idamakanti,1 Patrick M. Wright,1 Jennifer Marshall-Neff,1 Michele L. Rollence,1 Glen R. Nemerow,2 Christine Mech,1 Anne Pinkstaff,1 Michele Kaloss,1 Michael Kaleko,1 Susan C. Stevenson.1 1Genetic Therapy, Inc., A Novartis Company, Gaithersburg, MD, United States; 2Department of Immunology, The Scripps Research Institute, La Jolla, CA, United States. ' E "
3 (
7
3 " -'@/ ( 1
'@0
'2 '@
C
* 3
@ $ α
. '2
="
'82 '@ @ -C( / 0
C( -AA A/ D
'82 0
'2
.
'2 %
'&65 '82 .
@ $ C
'&65 ) C( '@ '2
C(
E G
1
"
'@ G C(
S149